Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): A randomised phase 3 trial

The Lancet Oncology

Volumn 14, Issue 6, 2013, Pages 525-533

  Delarue, Richard ^a   Tilly, Hervé ^b   Mounier, Nicolas ^c   Petrella, Tony ^d   Salles, Gilles ^e,f   Thieblemont, Catherine ^g,h   Bologna, Serge ⁱ   Ghesquières, Hervé ^j   Hacini, Maya ^k   Fruchart, Christophe ^l   Ysebaert, Loïc ^m,n   Fermé, Christophe ^o   Casasnovas, Olivier ^p   Van Hoof, Achiel ^q   Thyss, Antoine ^r   Delmer, Alain ^s   Fitoussi, Olivier ^t   Molina, Thierry Jo ^a,u   Haioun, Corinne ^v,w   Bosly, André ^x  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b UNIVERSITÉ DE ROUEN   (France)

^c CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^d DIJON UNIVERSITY HOSPITAL   (France)

^e UNIVERSITÉ LYON 1   (France)

^f CNRS   (France)

^g SAINT LOUIS HOSPITAL   (France)

^h INSERM   (France)

ⁱ CHU NANCY BRABOIS   (France)

^j CENTRE LÉON BÉRARD   (France)

^k CENTRE HOSPITALIER DE CHAMBÉRY   (France)

^l CENTRE FRANÇOIS BACLESSE   (France)

^m CHU PURPAN   (France)

ⁿ CANCER RESEARCH CENTER OF TOULOUSE   (France)

^o INSTITUT GUSTAVE ROUSSY   (France)

^p HÔPITAL DU BOCAGE   (France)

^q Algemeen Ziekenhuis St Jan   (Belgium)

^r CENTRE ANTOINE LACASSAGNE   (France)

^s UNIVERSITÉ DE REIMS CHAMPAGNE ARDENNE   (France)

^t Polyclinique Bordeaux Nord   (France)

^u UNIVERSITÉ PARIS DESCARTES   (France)

^v HENRI MONDOR HOSPITAL   (France)

^w UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^x UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ALLERGY; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; COMPARATIVE STUDY; CONTROLLED STUDY; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; ELDERLY CARE; ERYTHROCYTE TRANSFUSION; EVENT FREE SURVIVAL; FEBRILE NEUTROPENIA; FEMALE; HEMATOLOGIC DISEASE; HUMAN; INFECTION; LARGE CELL LYMPHOMA; LUNG DISEASE; LYMPHATIC SYSTEM DISEASE; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROLOGIC DISEASE; NEUTROPENIA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SKIN DISEASE; SURVIVAL RATE; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; VASCULAR DISEASE; VOMITING;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHI-SQUARE DISTRIBUTION; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; EUROPE; FEMALE; HUMANS; INTENTION TO TREAT ANALYSIS; KAPLAN-MEIER ESTIMATE; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; PREDNISONE; PROPORTIONAL HAZARDS MODELS; TIME FACTORS; TREATMENT OUTCOME; VINCRISTINE;

EID: 84876987456     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(13)70122-0     Document Type: Article

References (25)

1. Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood 2006, 107:265-276.
2. Sehn LH, Donaldson J, Chhanabhai M, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 2005, 23:5027-5033.
3. Maloney DG Anti-CD20 antibody therapy for B-cell lymphomas. N Engl J Med 2012, 366:2008-2016.
4. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002, 346:235-242.
5. Habermann TM, Weller EA, Morrison VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006, 24:3121-3127.
6. Pfreundschuh M, Schubert J, Ziepert M, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 2008, 9:105-116. for the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL).
7. Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993, 328:1002-1006.
8. Pfreundschuh M, Trumper L, Kloess M, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 2004, 104:634-641.
9. Swerdlow AJ, Campo E, Harris ES, et al. World Health Organization classification of tumours of haematopoietic and lymphoid tissues 2008, IARC Press, Lyon.
10. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 1999, 17:1244-1253.
11. Bonnet C, Fillet G, Mounier N, et al. CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2007, 25:787-792.
12. Brusamolino E, Rusconi C, Montalbetti L, et al. Dose-dense R-CHOP-14 supported by pegfilgrastim in patients with diffuse large B-cell lymphoma: a phase II study of feasibility and toxicity. Haematologica 2006, 91:496-502.
13. Mey UJ, Maier A, Schmidt-Wolf IG, et al. Pegfilgrastim as hematopoietic support for dose-dense chemoimmunotherapy with R-CHOP-14 as first-line therapy in elderly patients with diffuse large B cell lymphoma. Support Care Cancer 2007, 15:877-884.
14. Kamel S, O'Connor S, Lee N, Filshie R, Nandurkar H, Tam CS High incidence of Pneumocystis jirovecii pneumonia in patients receiving biweekly rituximab and cyclophosphamide, adriamycin, vincristine, and prednisone. Leuk Lymphoma 2010, 51:797-801.
15. Tadmor T, McLaughlin P, Polliack A A resurgence of Pneumocystis in aggressive lymphoma treated with R-CHOP-14: the price of a dose-dense regimen?. Leuk Lymphoma 2010, 51:737-738.
16. Halaas JL, Moskowitz CH, Horwitz S, et al. R-CHOP-14 in patients with diffuse large B-cell lymphoma: feasibility and preliminary efficacy. Leuk Lymphoma 2005, 46:541-547.
17. Lyman GH, Dale DC, Friedberg J, Crawford J, Fisher RI Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study. J Clin Oncol 2004, 22:4302-4311.
18. Doorduijn JK, van der Holt B, van Imhoff GW, et al. CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma. J Clin Oncol 2003, 21:3041-3050.
19. Osby E, Hagberg H, Kvaloy S, et al. CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic Lymphoma Group randomized trial. Blood 2003, 101:3840-3848.
20. Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006, 24:3187-3205.
21. Cunningham D, Smith P, Mouncey P, et al. R-CHOP14 versus R-CHOP21: result of a randomized phase III trial for the treatment of patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma. Proc Am Soc Clin Oncol 2011, 29(suppl). abstr 8000.
22. Nowakowski GS, LaPlant B, Habermann TM, et al. Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: phase I study. Leukemia 2011, 25:1877-1881.
23. Ribrag V, Gisselbrecht C, Haioun C, et al. Efficacy and toxicity of 2 schedules of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone plus bortezomib in patients with B-cell lymphoma: a randomized phase 2 trial from the French Adult Lymphoma Study Group (GELA). Cancer 2009, 115:4540-4546.
24. 131Iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016. J Clin Oncol 2013, 31:314-320.
25. Pfreundschuh M, Held G, Zeynalova S, et al. Improved outcome of elderly poor-prognosis DLBCL patients with 6xCHOP-14 and 8 applications of rituximab (R) given over an extended period: results of the SMARTE-R-CHOP-14 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Blood 2011, 118. abstr 272a.